Psychological distress in patients attending an oncology clinic after definitive treatment for maxillofacial malignant neoplasia

Telfer, M.R.; Shepherd, Jonathan

doi:10.1016/s0901-5027(05)80664-2

Cited by 29 publications

(17 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This implies that abnormal expression and over expression of HER2/neu could not play a role in carcinogenesis process of HNSCC. This result is in accordance with some studies that found no HER2/neu over expression in HNSCC cases (Field et al, 1992;Mort et al, 1993;Ekberg et al, 2005;Angiero et al, 2008).…”

Section: Discussionsupporting

confidence: 93%

HER2/neu Expression in Head and Neck Squamous Cell Carcinoma Patients is not Significantly Elevated

Sardari¹,

Pardis²,

Andisheh-Tadbir³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: HER2/neu, a member of EGFR family, is over expressed in some tumors .The purpose of this study was to determine the salivary level and tissue expression of HER2/neu in patients with head and neck squamous cell carcinoma (HNSCC) and any correlation with clinicopathologic parameters. Methods: An enzymelinked immunosorbent assay (ELISA) was used to evaluate the salivary level and immunohistochemistry (IHC) to assess tissue expression of HER2/neu in 28 patients with HNSCC and 25 healthy controls. Results: The salivary levels of HER2/neu in HNSCC patients was not significantly higher than in the healthy controls (p>0.005). There was no apparent correlation in salivary HER2/neu level with clinicopathological features such as age, sex, grade, tumor size and nodal status. All HNSCC specimens were positive (membranous or/and cytoplasmic) for HER2/ neu, except one sample. Only one HNSCC specimen was stained in cytoplasm purely. All control specimens were membranous and cytoplasmic positive for HER2/neu. There was a significant difference between cytoplasmic staining in case and control groups (p-value<0.05). Conclusion: In our cases, no overexpression of HER2/neu was observed. Thus, our findings suggested that the use of Her-2 as a salivary marker of HNSCC cannot be recommended.

show abstract

Section: Discussionsupporting

confidence: 93%

HER2/neu Expression in Head and Neck Squamous Cell Carcinoma Patients is not Significantly Elevated

Sardari¹,

Pardis²,

Andisheh-Tadbir³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…This prevalence of psychological distress is similar to what has been shown in the literature among head and neck cancer patients. In a prospective study by Telfer et al, using the HAD scale to screen for anxiety and depression in 40 head and neck cancer patients, 33% of the patients had high anxiety while 15% were depressed (84). In a more recent study using the HAD scale to evaluate patients' psychological status, Hassanein et al reported that 16% of the patients included in their study were anxious and 19% were depressed (85 Anxiety in cancer patients most frequently arises from patients' fear of metastasis, unpredictability about the future, fear of physical suffering and the loss of control over their own body (87).…”

Section: Psychological Distressmentioning

confidence: 99%

Coping and psychological distress among head and neck cancer patients

Elani

2010

Support Care Cancer

View full text Add to dashboard Cite

“…Survival rates, however, have not improved over the last 20 years and 50 -70% of patients die within 5 years due to local recurrences, metastasis and a second primary cancer (Day and Blot, 1992). Surgery is still the treatment of choice, but often results in chronic pain, speech and swallowing impediments, and irreparable, disfiguring impairments (Mort Telfer and Shepherd, 1993;de Cassia Braga Ribeiro et al, 2003).…”

mentioning

confidence: 99%

Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas

et al. 2005

View full text Add to dashboard Cite

This paper illustrates the efficacy of DNA vaccination through electroporation in the prevention of oral transplantable carcinoma in Syrian hamsters. At 21 and 7 days before tumour challenge, 19 hamsters were vaccinated with plasmids coding for the extracellular and transmembrane domains of rat HER-2 receptor (EC-TM plasmids), whereas 19 control hamsters were injected intramuscularly with the empty plasmid. Immediately following plasmid injection, hamsters of both groups received two square-wave 25 ms, 375 V cm À1 electric pulses via two electrodes placed on the skin of the injection area. At day 0, all hamsters were challenged in the submucosa of the right cheek pouch with HER-2-positive HCPC I cells established in vitro from an 7,12-dimethylbenz[a]anthraceneinduced oral carcinoma. This challenge gave rise to HER-2-positive buccal neoplastic lesions in 14 controls (73.37%), compared with only seven (36.8%, Po0.0027) vaccinated hamsters. In addition, the vaccinated hamsters displayed both a stronger proliferative and cytotoxic response than the controls and a significant anti-HER-2 antibody response. Most of the hamsters that rejected the challenge displayed the highest antibody titres. These findings suggest that DNA vaccination may have a future in the prevention of HER-2-positive human oral cancer.

show abstract

Psychological distress in patients attending an oncology clinic after definitive treatment for maxillofacial malignant neoplasia

Cited by 29 publications

References 11 publications

HER2/neu Expression in Head and Neck Squamous Cell Carcinoma Patients is not Significantly Elevated

HER2/neu Expression in Head and Neck Squamous Cell Carcinoma Patients is not Significantly Elevated

Coping and psychological distress among head and neck cancer patients

Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas

Contact Info

Product

Resources

About